

Reporting adverse reactions

This medicine is subject to additional safety monitoring. This will allow quick identification of new safety information. You can also help by reporting any side effects you may get via the Yellow Card Scheme: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

Healthcare Professionals – Please also consult the Alunbrig[®] Summary of Product Characteristics for more information.

Record your details here:

Your name: _____

Doctor's name (who prescribed Alunbrig[®]): _____

Doctor's phone number: _____

Hospital: _____

Date of first Alunbrig[®] treatment: _____

Date of last Alunbrig[®] treatment (if you are no longer taking Alunbrig[®]): _____

IN CASE OF EMERGENCY please contact:

Name: _____

Phone number: _____

Alunbrig[®] ▼ (brigatinib)

Important

- This patient alert card contains important safety information that you need to be aware of when you are using Alunbrig[®].
- Always carry this alert card with you whilst you are receiving treatment and for a month after your last treatment with Alunbrig[®].
- Show this card to any doctor or healthcare professional that you see.
- Record your details on the back of this card.

Important information for Patients

Alunbrig® has been given to you to slow down the growth and spread of your lung cancer. When taking Alunbrig® you might get lung or breathing problems.

- Some of the symptoms might be similar to your lung cancer or other lung diseases you may have.
- Some of these are serious and will need immediate medical care.
- These side effects are more likely in the first 7 days after starting your treatment with Alunbrig®.

Important information for Patients

Talk to your doctor straight away if you get any of the following symptoms or if any of these symptoms persist or worsen:

- difficulty breathing
- being short of breath
- pain in your chest
- coughing
- high temperature (fever)

Not all possible side effects are listed on this card.

Please read your Alunbrig® package leaflet for more information about side effects.

Information for Healthcare Professionals

This patient is being treated with Alunbrig® to treat advanced stage ALK+ non-small cell lung cancer.

- Alunbrig® is associated with the occurrence of serious pulmonary adverse reactions such as interstitial lung disease and pneumonitis.
- These pulmonary reactions can occur early, often within the first 7 days of treatment.
- Symptoms of these pulmonary reactions can be confused with symptoms of the patient's underlying pulmonary disease including lung cancer.

Should the patient experience any pulmonary symptoms, **contact the patient's Alunbrig® prescriber** (details in this PAC) straight away to be sure that the correct action is taken.